---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005714"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:49:14.901088+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023

## Summary
- Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.
- Net loss Q4 2022 $38.8M ($0.74/share) vs $51.8M ($1.00/share) in Q4 2021; full year net loss $168.1M ($3.23/share).
- R&D expenses FY2022 $142.8M, up from $121.3M in FY2021; G&A expenses $28.2M vs $28.7M.
- Enrollment continues in ACHIEVE (DYNE-101 in DM1) and DELIVER (DYNE-251 in DMD) Phase 1/2 registrational trials.
- Initial data from MAD placebo-controlled portions of both trials anticipated in second half of 2023.

## SEC filing metadata
- accession: 0000950170-23-005714
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/dyn-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005714
- JSON: https://secwatch.observer/filing/0000950170-23-005714.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005714.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share., EPS $0.74 per basic and diluted share.
  - Period: the quarter ended December 31, 2022
  - Net income: Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.
  - EPS: $0.74 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm
- Earnings Releases
  Dyne Therapeutics, Inc. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share., EPS $3.23 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.
  - EPS: $3.23 per basic and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.